COMMUNIQUÉS West-GlobeNewswire

Treace Announces Participation at Stifel 2024 Healthcare Conference

18/11/2024 - 22:46

PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Trent Renta Promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia

18/11/2024 - 22:44

ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics is proud to announce the promotion of Trent Renta to Chief Operating Officer (COO). Trent has been a dedicated member of the Olansky team [...]

Publication relating to transparency notifications

18/11/2024 - 22:30

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]

Publication relative à des notifications de transparence

18/11/2024 - 22:30

INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 18 novembre 2024 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

18/11/2024 - 22:05

CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]

OraSure to Participate in Upcoming Investor Conference

18/11/2024 - 22:05

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment [...]

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18/11/2024 - 22:05

Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN [...]

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

18/11/2024 - 21:20

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction [...]

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

18/11/2024 - 18:00

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, [...]

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

18/11/2024 - 18:00

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » Cette journée, organisée en collaboration avec Phage Canada et réunissant des experts [...]

Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List

18/11/2024 - 17:20

CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s Cleveland Business has recognized leading professionals in the Northeast Ohio region that have been celebrated as part of the 40 Under 40 program. [...]

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

18/11/2024 - 17:15

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at [...]

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

18/11/2024 - 17:00

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA granted both [...]

Novo Nordisk A/S - share repurchase programme

18/11/2024 - 16:08

Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease

18/11/2024 - 15:16

Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American Academy of [...]

SoldierStrong Announces Annual SoldierScholar Recipients for 2024

18/11/2024 - 15:00

STAMFORD, Conn., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Delivering on its commitment to assist military veterans in taking a significant academic step forward in life after service, the national nonprofit SoldierStrong today [...]

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

18/11/2024 - 14:45

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – - Top-line [...]

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18/11/2024 - 14:40

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal [...]

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

18/11/2024 - 14:30

ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine Models Proprietary Dagger ® Technology Enables ALLO-329 to Overcome [...]